Natural Lignan Vitexin B-1 Induces Cell Cycle Arrest and Apoptosis via Targeting HSP90 Through EGFR Pathway in...

Area of Science:

• Natural Products Chemistry
• Molecular Pharmacology
• Oncology

Background:

• Natural products are a rich source of anticancer drug leads.
• Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality worldwide.
• Targeting molecular pathways like HSP90 and EGFR is crucial for effective NSCLC treatment.

Purpose of the Study:

• To identify novel small molecules with anticancer potential from a natural product library.
• To investigate the mechanism of action of Vitexin B-1 (VB-1) in NSCLC.
• To evaluate VB-1 as a potential therapeutic agent for NSCLC.

Main Methods:

• Screening of 2000 small molecules for cytotoxicity against NSCLC cell lines.
• Network pharmacological analysis to identify molecular targets.
• Molecular docking and fluorescence polarization assays to confirm target binding.
• Western blot analysis to assess effects on signaling pathways.

Main Results:

• Vitexin B-1 (VB-1) exhibited significant growth inhibition across multiple cancer cell lines, including NSCLC.
• VB-1 induced apoptosis and G2/M cell cycle arrest in HCC827 cells.
• HSP90AA1 and HSP90AB1 were identified as key molecular targets of VB-1.
• VB-1 downregulated EGFR and downstream signaling proteins (AKT, ERK, BRAF).

Conclusions:

• Vitexin B-1 (VB-1) demonstrates potent antitumor activity against NSCLC by inhibiting HSP90AA1 and HSP90AB1.
• VB-1 exerts its effects through the EGFR signaling pathway.
• VB-1 shows promise as a potential therapeutic agent for NSCLC, especially in EGFR-mutant cases.